Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke

Cerebrovascular Diseases

Volumn 36, Issue 4, 2013, Pages 299-305

  Koga, Masatoshi ^a   Arihiro, Shoji ^a   Miyashita, Fumio ^b   Yamamoto, Haruko ^c   Yamada, Naoaki ^b   Nagatsuka, Kazuyuki ^a   Minematsu, Kazuo ^b   Toyoda, Kazunori ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Department of Cerebrovascular Medicine ^*  (United States)

^c Research and Development Initiative Center   (United States)

Author keywords

Acute ischemic stroke; C reactive protein; High density lipoprotein cholesterol; Intravenous thrombolysis; Recanalization

Indexed keywords

ALTEPLASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALBERTA STROKE PROGRAM EARLY COMPUTED TOMOGRAPHY SCORE; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIFFUSION WEIGHTED IMAGING; EMBOLECTOMY SYSTEM; FEMALE; FOLLOW UP; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RECANALIZATION; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; THROMBECTOMY DEVICE; VITAL SIGN;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBRAL ANGIOGRAPHY; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; DIFFUSION MAGNETIC RESONANCE IMAGING; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 84885517721     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000355054     Document Type: Article

References (38)

1. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (JMARS). Stroke 2010; 41: 1984-1989.
2. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K: Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40: 3591-3595.
3. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
4. Hill MD, Buchan AM: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-1312.
5. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
6. Nakashima T, Toyoda K, Koga M, Matsuoka H, Nagatsuka K, Takada T, Naritomi H, Minematsu K: Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/ kg) alteplase therapy for ischaemic stroke. Int J Stroke 2009; 4: 425-431.
7. Koga M, Toyoda K, Nakashima T, Hyun BH, Uehara T, Yokota C, Nagatsuka K, Naritomi H, Minematsu K: Carotid duplex ultrasonography can predict outcome of intravenous alteplase therapy for hyperacute stroke. J Stroke Cerebrovasc Dis 2011; 20: 24-29.
8. Hirano T, Sasaki M, Mori E, Minematsu K, Nakagawara J, Yamaguchi T: Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients: exploratory analysis of the Japan Alteplase Clinical Trial II. Stroke 2010; 41: 2828-2833.
9. Rha JH, Saver JL: The impact of recanalization on ischemic stroke outcome: A meta-analysis. Stroke 2007; 38: 967-973.
10. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432-1438.
11. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP, Frei D, Grobelny T, Hellinger F, Huddle D, Kidwell C, Koroshetz W, Marks M, Nesbit G, Silverman IE: Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205-1212.
12. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761-2768.
13. Alshekhlee A, Pandya DJ, English J, Zaidat OO, Mueller N, Gupta R, Nogueira RG: Merci mechanical thrombectomy retriever for acute ischemic stroke therapy: literature review. Neurology 2012; 79:S126-S134.
14. Tarr R, Hsu D, Kulcsar Z, Bonvin C, Rufenacht D, Alfke K, Stingele R, Jansen O, Frei D, Bellon R, Madison M, Struffert T, Dorfler A, Grunwald IQ, Reith W, Haass A: The POST trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J Neurointerv Surg 2010; 2: 341-344.
15. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368: 893-903.
16. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL: A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013; 368: 914-923.
17. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO: Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241-1249.
18. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS: Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet 2012; 380: 1231-1240.
19. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, Mc-Mullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H: Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
20. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T: Effects of 0.6 mg/ kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41: 461-465.
21. Niewada M, Kobayashi A, Sandercock PA, Kaminski B, Czlonkowska A: Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trial. Neuroepidemiology 2005; 24: 123-128.
22. Maeda K, Toyoda K, Minematsu K, Kobayashi S: Effects of sex difference on clinical features of acute ischemic stroke in Japan. J Stroke Cerebrovasc Dis 2012, Epub ahead of print.
23. Kent DM, Buchan AM, Hill MD: The gender effect in stroke thrombolysis: of cases, controls, and treatment-effect modification. Neurology 2008; 71: 1080-1083.
24. Meseguer E, Mazighi M, Labreuche J, Arnaiz C, Cabrejo L, Slaoui T, Guidoux C, Olivot JM, Abboud H, Lapergue B, Raphaeli G, Klein IF, Lavallee PC, Amarenco P: Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: A clinical registry study and systematic review. Stroke 2009; 40: 2104-2110.
25. Mendonça N, Rodriguez-Luna D, Rubiera M, Boned-Riera S, Ribo M, Pagola J, Pineiro S, Meler P, Alvarez-Sabin J, Montaner J, Molina CA: Predictors of tissue-type plasminogen activator nonresponders according to location of vessel occlusion. Stroke 2012; 43: 417-421.
26. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV: Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38: 948-954.
27. Kim YS, Garami Z, Mikulik R, Molina CA, Alexandrov AV: Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 2005; 36: 869-871.
28. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, Watson T, Goyal M, Demchuk AM: Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41: 2254-2258.
29. Endo K, Koga M, Sakai N, Yamagami H, Furui E, Matsumoto Y, Shiokawa Y, Yoshimura S, Okada Y, Nakagawara J, Hyogo T, Hasegawa Y, Nagashima H, Fujinaka T, Hyodo A, Terada T, Toyoda K: Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era. J Stroke Cerebrovasc Dis 2013; 22: 805-810.
30. Sanossian N, Saver JL, Navab M, Ovbiagele B: High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 2007; 38: 1104-1109.
31. Lapergue B, Moreno JA, Dang BQ, Coutard M, Delbosc S, Raphaeli G, Auge N, Klein I, Mazighi M, Michel JB, Amarenco P, Meilhac O: Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke 2010; 41: 1536-1542.
32. Paterno R, Ruocco A, Postiglione A, Hubsch A, Andresen I, Lang MG: Reconstituted highdensity lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004; 17: 204-211.
33. Ren S, Shen GX: Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 1688-1693.
34. Makihara N, Okada Y, Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Hasegawa Y, Kario K, Okuda S, Naganuma M, Toyoda K: Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry. Cerebrovasc Dis 2012; 33: 240-247.
35. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
36. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-2579.
37. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
38. Singh U, Devaraj S, Jialal I: C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005; 25: 2216-2221.